The Delhi High Court has directed the Central Drugs Standard Control Organisation (CDSCO) to address safety concerns regarding Zydus Lifesciences' semaglutide injections, marketed as Semaglyn, Alterme, and Mashema. A petition filed by diabetes patient Jyoti Shrivastava alleges that Zydus deviated from established global practices by using a formulation that lacks pre-filled, pre-calibrated pen devices, which are standard for safe administration. The petition claims this design increases the risk of incorrect dosing, potentially leading to serious health complications. Justice Purushaindra Kumar Kaurav stated that Shrivastava should submit a detailed representation to the CDSCO, which is required to consider her concerns and respond within two months. The approval process for Zydus' semaglutide, which addresses both Type 2 Diabetes and weight management, has been criticized for not adhering to separate clinical evaluation standards, raising questions about its safety and efficacy.